Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Baron Oil, Bezant Resources,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Baron Oil, Bezant Resources,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Pound/Dollar, Boston International Holdings,
Zak Mir takes a charting look at some of the small caps stocks of the week on the London stock market. Today’s selection of charts is FTSE 100, Pound /
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec®
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an operational update on its development
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce a further update on its recent
ANGLE (AGL), a liquid biopsy company, announced the completion of the placing announced on 14 July 2022 to raise £20 million, together with a subscription in the capital of the
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce an update on its current work
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Atome, Clontarf, Cap-XX, Jersey, IMC, McColls,
All eyes are on Okyo (OKYO) as the biotechnology company announced that the patent entitled “Methods and Systems for Designing and/or Characterizing Soluble Lipidated has been issued by the United
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce its audited results for the year